PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Inclusion Criteria: 1. Male and female, aged 18-65; 2. relapsed/refractory DLBCL patients after autologous stem cell transplantation; 3. Laboratory tests (blood tests, liver and renal function) meet the following requirements: 1. Blood tests: white blood cell count ≥ 3.0 × 109 / L, absolute neutrophil count ≥ 1.5 × 109 / L, hemoglobin ≥ 90g / L, platelet ≥ 75 × 109 / L 2. Liver function: transaminase ≤ 2.5 × upper limit of normal value, bilirubin ≤ 1.5 × upper limit of normal value; 3. Renal function: serum creatinine 44-133 mmol / L; 4. The score of ECOG was 0-2; 5. The subject or his legal representative must provide written informed consent before the special examination or procedure of the study. Exclusion Criteria: 1. Pregnant or lactating women; 2. Severe complications or infection; 3. Lymphoma involving central nervous system; 4. Participate in other clinical trials at the same time; 5. According to the judgment of the researcher, the patients who are not suitable for this study were selected.